Aug 10, 2020
The influx of companies, the launch of pipeline therapies, and the legalization of marijuana/ cannabis are the major drivers of the medical marijuana market. Cannabis, popularly known as Marijuana, is the most commonly used illicit drug after alcohol. More than 150 Million people regularly smoke marijuana. Appr...
Read More...
Aug 08, 2017
Failure of Phase II cannabidiol trial leads to loss for Zynerba Zynerba Pharmaceuticals’ phase II trial for transdermal cannabinoid candidate missed all its endpoints, as it failed to hit a single goal or show a dose response raises big doubts about the drug's prospects. This news eroded around 55% off Zynerba’s sto...
Read More...
Sep 30, 2016
GW Pharmaceuticals, a UK based company, believes in growing its own cannabis plants, search for its ingredients and then come up with medicines that help the company in taking one more step towards approval of Epidiolex, as seen in the announcement of positive phase 3 trial results earlier this week. The drug is fo...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper